Epigenetic Regulation of BDNF in Major Depression
The investigators will (1) detect the associations between brain-derived neurotrophic factor (BDNF) DNA methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive disorder (MDD) patients, (2) check the correlation between blood BDNF protein and RNA and BDNF rs6265 gene, and (3) discuss the possible mechanisms of epigenetic regulation of BDNF in Taiwanese major depressive patients.
Major Depressive Disorder
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Epigenetic Regulation of Brain-Derived Neurotropic Factor (BDNF) in Patients With Major Depression|
- Brain-derived Neurotrophic Factor (BDNF) DNA Methylation of Major Depressive Disorder (MDD) Patients and Healthy Controls [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]averaged percentage of methylation at each CpG site listed
- Histone Modification of MDD Patients Before and After Treatment and With Healthy Controls [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Chromatin immunoprecipitation (ChIP) was used to measure histone modification. The unit of our given machine is relative quantification, and a higher value indicated increased histone modification. The detailed method could be found in:
Huebert DJ, Kamal M, O'Donovan A, Bernstein BE: Genome-wide analysis of histone modifications by ChIP-on-chip. Methods 2006; 40: 365-369.
- BDNF Levels of MDD Patients Before and After Treatment and Healthy Controls [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Serum BDNF levels were measured. MDD patients received antidepressant treatment, a standard biological management. Nothing novel (such as experimental drugs or management) is introduced in the treatment, so the research design is observational (of standard treatment).
The choice of antidepressant drugs depended on the need of patients in natural treatment procedure. They included selective serotonin reuptake inhibitors (SSRI), eg. fluoxetine or paroxetine.
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2010|
|Study Completion Date:||May 2013|
|Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
|Major depressive patients|
Brain-derived neurotrophic factor (BDNF) had been chosen as a candidate gene for a development of major depressive disorder (MDD). BDNF had been reported to have an important role on neuronal plasticity, axonal growth and connectivity, and participating in the local response to various types of neuronal stressors. BDNF also influences the differentiation of neurons.
In the past studies, the investigators had found that major depressive women had lower serum BDNF protein levels than healthy controls, and their BDNF levels became significantly increased after antidepressant treatments. In addition, some authors had found that reduced expression of BDNF was noted in postmortem brain of completed suicide subjects. Suicidal major depressive patients also had lower plasma BDNF levels than non-suicidal major depressive patients. These findings suggested that BDNF might play an important role in the suicidal behavior.
However, in past studies, the results did not fully explain why major depressive patients with same genotypes had different clinical expression, including the severity of depression, with/without suicide, and the treatment response. Recently, some papers found that there were relationships between epigenetic regulation, including DNA methylation and histone modification, and psychopathology of major depression. Therefore, we try to investigate the relationships between epigenetic regulation of BDNF and major depression.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01182103
|Department of Psychiatry, Chang Gung Memorial Hospital|
|Kaohsiung, Taiwan, 833|
|Principal Investigator:||Tiao-Lai Huang, M.D.||Chang-Gung Memorial Hospital, Kaohsiung|